Fragment 176-191

Description

Fragment 176-191 is a synthetic C-terminal fragment of human growth hormone that promotes fat metabolism. It has shown promise in research for reducing blood sugar and aiding cartilage regeneration.

Overview

Fragment 176-191 is a specially engineered synthetic peptide derived from the human growth hormone molecule, specifically targeting the amino acid sequence from position 176 to 191. Unlike full growth hormone, this fragment is designed to primarily exert a fat-burning effect without inducing the typical growth-promoting or insulin-modulating actions often associated with HGH. Due to limited direct research on Fragment 176-191, much of our understanding of its potential actions and safety profile is inferred from studies of the structurally similar peptide, AOD9604 (Fragment 177-191). Early animal studies suggest that Fragment 176-191, or its close analog, can effectively reduce body fat and weight in obese subjects by enhancing the breakdown of lipids. This effect is believed to be mediated by an increase in beta-3 adrenergic receptors, which play a role in regulating fat metabolism. Furthermore, investigations into its impact on glucose metabolism have revealed that this peptide can help in lowering blood sugar, potentially offering a therapeutic avenue for conditions like prediabetes and type 2 diabetes by selectively increasing insulin in the plasma without altering insulin sensitivity. Beyond its metabolic effects, Fragment 176-191 also demonstrates promise in joint health. Research, primarily with AOD9604, indicates a capacity to enhance cartilage regeneration, which could lead to novel treatments for osteoarthritis and other degenerative joint conditions. Researchers are actively exploring whether these benefits observed in animal models and with its analog will translate to similar positive outcomes in human application.

Mechanism of Action

This peptide mimics the lipolytic action of growth hormone by increasing energy expenditure and fat oxidation, without affecting blood glucose levels or insulin sensitivity. It also appears to stimulate myoblast generation, which is integral to muscle tissue repair.

Benefits

• •Supports fat loss
• •May reduce blood sugar levels
• •Promotes cartilage repair
• •Does not significantly impact insulin sensitivity
• •Avoids common HGH side effects

Dosing Notes

Fragment 176-191 is typically administered subcutaneously once daily in the morning on an empty stomach, or split into two doses, morning and night, also on an empty stomach, over approximately four weeks.

Reported Side Effects

• •Headache
• •Fatigue
• •Hypoglycemia
• •Dizziness
• •Nasopharyngitis
• •Cough
• •Lethargy
• •Tonsillitis
• •Abdominal pain
• •Application site reaction
• •Sore throat
• •Injection site bruising
• •Rhinitis seasonal
• •Anorexia
• •Injection site pain

Safety Notes

Current research on Fragment 176-191 is limited, and its full safety profile in humans is not yet established. However, studies on the closely related peptide AOD9604 indicate it generally avoids side effects commonly associated with full growth hormone, such as increased insulin resistance, hypertension, or edema. It is not known to impact long bone growth or IGF-1 levels. Despite encouraging safety data from analog studies, Fragment 176-191 is not FDA-approved for human use and should only be handled by qualified research professionals.

Scientific References